What is JNJ's current stock price?

As of now, JNJ is trading at $206.37, with a daily change of -0.93%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

JNJ Stock Analysis & IQ Rating | Johnson & Johnson

JNJ

Johnson & Johnson

$206.37

-$1.94 | -0.93%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$215.19

MKT CAP

$496.88B

52W Low

$140.68

VOL

$7.71M

P/E Ratio

19.92

AVG VOL

$9.12M

RSI

55.52

TREND

Uptrend

JNJ Stock IQ

Login to see Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

JNJ Target Price

Login to display

Strengths

JNJ Rewards

Earnings are forecast to grow

JNJ Rewards

Upgraded on attractively valued

JNJ Rewards

Investors confidence is positive

JNJ Rewards

Outperform the market

JNJ Price Performance

$206.05 (+0.16%)

$179.71 (+14.84%)

$166.71 (+23.79%)

$143.66 (+43.65%)

1year

6month

3month

1month

JNJ Risk Level

JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

JNJ Analysts Opinion

JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

JNJ Analysts Opinion

JNJ Analysts opinion is positive and also has improved from the past 3 months

JNJ Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

79%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

75%

29%

80%

JNJ Street Sentiment

JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook

JNJ Performance Sentiment

Sentiments overview associated with JNJ events and the stock performance.

79%

14%

Positive

Negative

44 out of 56
events present

8 out of 56
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$206.37

Resistance
Price

$195.90

Current Price Range

$214.17

Show methods +

Linked to JNJ

IQ

Close Price

Change

NBTX

4.00

22.13

+0.14%

BLTE

3.66

156.00

+0.94%

ANNX

3.83

5.17

+7.26%

SNDX

3.98

20.77

+2.67%

REGN

4.20

767.96

+2.57%

JNJ Latest Analysis +

FDA Approves J&Js New 5-Minute Injection For Lung Cancer. On Wednesday the United States Food and Drug Administration (FDA) approved ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) the first and only subcutaneously (SC) administered therapy for epidermal growth factor receptor (EGFR)-.Rybrevant Faspro is approved for all indications for which Rybrevant is approved.Compared to intravenous (IV) delivery Rybrevant Faspro offers significantly higher patient convenience and lower :Reducing ad

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant. JNJ wins FDA approval for a subcutaneous version of Rybrevant cutting treatment time to minutes and boosting convenience across NSCLC indications.

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment. J&J ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines approvals and partnerships.

Thu Dec 18, 2025

$208.31 | -0.99%

Potential

Noteworthy ETF Inflows: IWX JNJ BAC WFC. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell Top 200 Value ETF (Symbol: IWX) where we have detected an approximate $322.4 million dollar inflow -- thats a 10.6% increase week ov

Thu Dec 18, 2025

$208.31 | -0.99%

Potential

J&J wins FDA nod for Rybrevant injectable in lung cancer.

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

FDA Approves Expanded Use Of Johnson & Johnsons TRUFILL N-BCA For Subdural Hematoma . (RTTNews) - Johnson & Johnson MedTech the medical technology arm of Johnson & Johnson (J&J) on Thursday said the United States Food and Drug Administration (FDA) has approved an expanded indication for its TRUFILL n-BCA Liquid Embolic System. The device is now cleared for embolization of

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

United States FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer. RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO Dec. 18 2025 /PRNewswire/ -- Halozyme Therapeutics Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the United States Food and Drug Administration...

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

FDA Approves Johnson & Johnsons RYBREVANT FASPRO First Subcutaneous Therapy For EGFR-Mutated NSCLC . (RTTNews) - Johnson & Johnson (JNJ) announced that the United States Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutat

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

BofA Sees J&Js Premium Multiple as Justified. Johnson &. Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15 BofA raised its price target on Johnson &. Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&.Js premium multiple looks appropriate for its growth plus asset mix. It [….]

Wed Dec 17, 2025

$210.33 | +0.50%

Activity

Rating

Notable Monday Option Activity: BBY JNJ AMC. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Best Buy Inc (Symbol: BBY) where a total of 19800 contracts have traded so far representing approximately 2.0 million underlying shares. That amounts to about 44% of

Mon Dec 15, 2025

$214.17 | +1.19%

Momentum

FAQ About JNJ Stock Insights

What is JNJ current stock price?

What are JNJ stock strengths?

What is JNJ Risk Level?

What is JNJ market cap and volume?

What is JNJ current Stock IQ?

Should I buy JNJ stock right now?

Is JNJ a Strong Buy right now?

What does a 'Strong Buy' rating mean for JNJ?

What does a 'Strong Sell' rating mean for JNJ?

What factors influence JNJ's Stock IQ?

Explore our JNJ Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored JNJ Stock Strategies
Effective Risk Management

FIND US ON

Receive our JNJ Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

JNJ

Johnson & Johnson

Current Price

$206.37

-$1.94 | -0.93%

52W High

$215.19

MKT CAP

$496.88B

52W Low

$140.68

VOL

$7.71M

P/E Ratio

19.92

AVG VOL

$9.12M

RSI

55.52

TREND

Uptrend

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

JNJ Rewards

Earnings are forecast to grow

JNJ Rewards

Upgraded on attractively valued

JNJ Rewards

Investors confidence is positive

JNJ Rewards

Outperform the market

Linked to JNJ

Symbol

IQ

Close

Change

NBTX

4.00

22.13

+0.14%

BLTE

3.66

156.00

+0.94%

ANNX

3.83

5.17

+7.26%

SNDX

3.98

20.77

+2.67%

REGN

4.20

767.96

+2.57%

JNJ Price Performance

$206.05 (+0.16%)

$179.71 (+14.84%)

$166.71 (+23.79%)

$143.66 (+43.65%)

1year

6month

3month

1month

JNJ Analysts Opinion

JNJ Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

JNJ Analysts Opinion

JNJ Analysts opinion is positive and also has improved from the past 3 months

JNJ Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

79%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

75%

29%

80%

JNJ Street Sentiment

JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook

JNJ Risk Level

JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

JNJ Performance Sentiment

Sentiments overview associated with JNJ events and the stock performance.

79%

14%

Positive

Negative

44 out of 56
events present

8 out of 56
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$206.37

Resistance
Price

$195.90

Current Price Range

$214.17

Show methods +

JNJ Stock IQ

Login to unlock Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

JNJ Latest Analysis

FDA Approves J&Js New 5-Minute Injection For Lung Cancer. On Wednesday the United States Food and Drug Administration (FDA) approved ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) the first and only subcutaneously (SC) administered therapy for epidermal growth factor receptor (EGFR)-.Rybrevant Faspro is approved for all indications for which Rybrevant is approved.Compared to intravenous (IV) delivery Rybrevant Faspro offers significantly higher patient convenience and lower :Reducing ad

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant. JNJ wins FDA approval for a subcutaneous version of Rybrevant cutting treatment time to minutes and boosting convenience across NSCLC indications.

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment. J&J ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines approvals and partnerships.

Thu Dec 18, 2025

$208.31 | -0.99%

Potential

Noteworthy ETF Inflows: IWX JNJ BAC WFC. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell Top 200 Value ETF (Symbol: IWX) where we have detected an approximate $322.4 million dollar inflow -- thats a 10.6% increase week ov

Thu Dec 18, 2025

$208.31 | -0.99%

Potential

J&J wins FDA nod for Rybrevant injectable in lung cancer.

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

FDA Approves Expanded Use Of Johnson & Johnsons TRUFILL N-BCA For Subdural Hematoma . (RTTNews) - Johnson & Johnson MedTech the medical technology arm of Johnson & Johnson (J&J) on Thursday said the United States Food and Drug Administration (FDA) has approved an expanded indication for its TRUFILL n-BCA Liquid Embolic System. The device is now cleared for embolization of

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

United States FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer. RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO Dec. 18 2025 /PRNewswire/ -- Halozyme Therapeutics Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the United States Food and Drug Administration...

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

FDA Approves Johnson & Johnsons RYBREVANT FASPRO First Subcutaneous Therapy For EGFR-Mutated NSCLC . (RTTNews) - Johnson & Johnson (JNJ) announced that the United States Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutat

Thu Dec 18, 2025

$208.31 | -0.99%

Activity

BofA Sees J&Js Premium Multiple as Justified. Johnson &. Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15 BofA raised its price target on Johnson &. Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&.Js premium multiple looks appropriate for its growth plus asset mix. It [….]

Wed Dec 17, 2025

$210.33 | +0.50%

Activity

Rating

Notable Monday Option Activity: BBY JNJ AMC. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Best Buy Inc (Symbol: BBY) where a total of 19800 contracts have traded so far representing approximately 2.0 million underlying shares. That amounts to about 44% of

Mon Dec 15, 2025

$214.17 | +1.19%

Momentum

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of JNJ. We're here to help you make informed investment decisions today.

FIND US ON

Receive our JNJ Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

JNJ Stock trends

JNJ Stock performance

JNJ Stock analysis

JNJ investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

JNJ Stock Analysis & IQ Rating | Johnson & Johnson

JNJ Stock IQ

JNJ Target Price

JNJ Risk Level

JNJ Analysts Opinion

JNJ Street Sentiment

JNJ Performance Sentiment

Technical Price Levels

Explore our JNJ Stock insights

Receive our JNJ Daily Alerts

JNJ Street Sentiment

JNJ Risk Level

Technical Price Levels

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of JNJ. We're here to help you make informed investment decisions today.

Receive our JNJ Daily Alerts

JNJ Alerts